David E Greenberg
Overview
Explore the profile of David E Greenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koch R, Barth J, Clark A, Desai D, Kim J, Pybus C, et al.
Microbiol Spectr
. 2024 Nov;
13(1):e0038324.
PMID: 39601576
Importance: While there have been several studies that attempt to find clinical predictors of outcomes in patients hospitalized with bacterial infections, less has been done to combine clinical data with...
2.
Somawardana I, Prasad B, Kay W, Hunt C, Adams J, Kawaguchi B, et al.
J Infect
. 2024 Sep;
89(5):106271.
PMID: 39278276
Objectives: We aimed to evaluate the effectiveness of alternating magnetic fields (AMF) combined with antibiotics in reducing Staphylococcus aureus biofilm on metal implants in a large animal model, compared to...
3.
Shaikh S, Lapin N, Prasad B, Sturge C, Pybus C, Pifer R, et al.
Sci Rep
. 2023 Dec;
13(1):22456.
PMID: 38105253
Prosthetic joint infection (PJI) is a complication of arthroplasty that results in significant morbidity. The presence of biofilm makes treatment difficult, and removal of the prosthesis is frequently required. We...
4.
Monogue M, Desai D, Pybus C, Sanders J, Clark A, Greenberg D
Microbiol Spectr
. 2023 Nov;
11(6):e0304723.
PMID: 37982634
No abstract available.
5.
Shropshire W, Amiji H, Bremer J, Anand S, Strope B, Sahasrabhojane P, et al.
Microbiol Spectr
. 2023 Oct;
11(6):e0222123.
PMID: 37800937
The increased feasibility of whole-genome sequencing has generated significant interest in using such molecular diagnostic approaches to characterize difficult-to-treat, antimicrobial-resistant (AMR) infections. Nevertheless, there are current limitations in the accurate...
6.
Monogue M, Sanders J, Pybus C, Kim J, Zhan X, Clark A, et al.
JAC Antimicrob Resist
. 2023 Jul;
5(4):dlad083.
PMID: 37441352
Objectives: Cystic fibrosis (CF) patients are often colonized with . During treatment, can develop subpopulations exhibiting variable antimicrobial (ABX) susceptibility patterns. Heteroresistance (HR) may underlie reported discrepancies between susceptibility results...
7.
Kollef M, Dupont H, Greenberg D, Viale P, Echols R, Yamano Y, et al.
Int J Antimicrob Agents
. 2023 Jun;
62(2):106882.
PMID: 37301312
Carbapenem-resistant Acinetobacter baumannii (CRAB) has been classified by the World Health Organization as being in the critical category of pathogens requiring urgent new antibiotic treatment options. Cefiderocol, the first approved...
8.
Ciarolla A, Lapin N, Williams D, Chopra R, Greenberg D
Antibiotics (Basel)
. 2023 Jan;
12(1).
PMID: 36671255
Prosthetic joint infection (PJI) presents several clinical challenges. This is in large part due to the formation of biofilm which can make infection eradication exceedingly difficult. Following an extensive literature...
9.
Kim K, Narasimhan M, Mahimainathan L, Zhang R, Araj E, Kim E, et al.
Front Immunol
. 2022 Nov;
13:1020165.
PMID: 36389788
Background: Immunocompromised (IC) patients show diminished immune response to COVID-19 mRNA vaccines (Co-mV). To date, there is no 'empirical' evidence to link the perturbation of translation, a rate-limiting step for...
10.
Maxwell D, Kim J, Pybus C, White L, Medford R, Filkins L, et al.
J Antimicrob Chemother
. 2022 Oct;
77(12):3321-3330.
PMID: 36227655
Background: Pseudomonas aeruginosa infection is the leading cause of death among patients with cystic fibrosis (CF) and a common cause of difficult-to-treat hospital-acquired infections. P. aeruginosa uses several mechanisms to...